RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more
RHYTHM Biosciences Ltd - Asset Resilience Ratio
RHYTHM Biosciences Ltd (RHY) has an Asset Resilience Ratio of 2.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how RHYTHM Biosciences Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down RHYTHM Biosciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$85.00K | 2.74% |
| Total Liquid Assets | AU$85.00K | 2.74% |
Asset Resilience Insights
- Limited Liquidity: RHYTHM Biosciences Ltd maintains only 2.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
RHYTHM Biosciences Ltd Industry Peers by Asset Resilience Ratio
Compare RHYTHM Biosciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for RHYTHM Biosciences Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for RHYTHM Biosciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 3.00% | AU$85.00K | AU$2.83 Million | +0.04pp |
| 2024-06-30 | 2.96% | AU$45.00K | AU$1.52 Million | +2.38pp |
| 2023-06-30 | 0.58% | AU$45.00K | AU$7.70 Million | +0.05pp |
| 2022-06-30 | 0.53% | AU$45.00K | AU$8.44 Million | -73.52pp |
| 2021-06-30 | 74.06% | AU$2.27 Million | AU$3.07 Million | +4.40pp |
| 2020-06-30 | 69.65% | AU$1.84 Million | AU$2.65 Million | -6.97pp |
| 2019-06-30 | 76.63% | AU$4.77 Million | AU$6.23 Million | -16.00pp |
| 2018-06-30 | 92.62% | AU$7.83 Million | AU$8.45 Million | -- |